secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003937
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics outlines 2024 priorities: WTX-124/330 data, cash runway through Q1 2025
--------------------------------------------------------------------------------

- WTX-124: updated monotherapy and initial combo data expected in 1H 2024; RDE selection and dose expansion planned.
- WTX-330: preliminary Phase 1 monotherapy data expected in Q2 2024.
- Preclinical candidates WTX-712 (IL-21) and WTX-518 (IL-18) advancing; preclinical data in 1H 2024.
- Cash guidance extended: resources sufficient through at least Q1 2025.
- Company seeking partners for non-oncology applications of INDUKINE platform, e.g., inflammatory diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524003937/0001193125-24-003937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312524003937/d873870d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer